Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
NMD Pharma, a Denmark-based biotechnology spinout from Aarhus University, raised €38m ($47m) in a series A round on Friday co-led by Roche Venture Fund, the corporate venturing arm of healthcare company Roche.
Inkef Capital, a Netherlands-based VC firm, co-led the round, which also featured Novo Seeds and Lundbeckfonden Emerge, respective early-stage investment units for pharmaceutical firms Novo and Lundbeck.
Founded in 2015, NMD Pharma is developing treatments for neuromuscular disorders that can cause debilitating fatigue and weakness, and…
